Jennifer Marvin-Peek

Jennifer Marvin-Peek

Auto-generated profile, based on publicly available information

Jennifer Marvin-Peek

Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 August 2025 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
CDCourtney Dinardo
Courtney Dinardo
JMJennifer Marvin-Peek
Jennifer Marvin-Peek
SLSanam Loghavi
Sanam Loghavi
KTKoichi Takahashi
Koichi Takahashi
GIGhayas C. Issa
Ghayas C. Issa
HKHagop M. Kantarjian
Hagop M. Kantarjian
PURPOSE: The development of targeted therapeutics has revolutionized treatment for elderly patients with AML. Two doublet regimens are approved in the frontline setting for intensive chemotherapy (IC)–ineligible AML: venetoclax (VEN) in combination with hypomethylating agent (HMA) therapy and azacitidine (AZA) plus ivosidenib (IVO) specifically for IDH1 -mutated AML. Although both regimens have improved AML outcomes, most patients will either not respond to frontline therapy or relapse, with dismal salvage outcomes. METHODS: We herein report on 60 newly diagnosed IC-ineligible patients treated at our institution with triplet regimens for isocitrate dehydrogenase ( IDH )–mutant AML. Patients received either AZA + VEN + IVO on NCT03471260 ( IDH1 -mutated patients only) or oral decitabine + VEN + IVO/enasidenib on NCT04774393 (arms for IDH1- and IDH2 -mutant disease, respectively). RESULTS: The triplet regimens were well tolerated with low early mortality (n = 1 [2%] in 60 days) and a similar safety profile to HMA + VEN and isocitrate dehydrogenase inhibitor doublet regimens. The composite complete remission rate (CRc) was 92% (55/60), with an overall response rate of 95% (57/60). With a median follow-up of 27.4 months, the median overall survival (OS) has not yet been reached. The 2-year OS was 69% with a 2-year cumulative incidence of relapse of 24%. Patients with treated-secondary AML (tsAML) experienced inferior outcomes with a CRc of 71% (12/17) and a 2-year OS of 34%; the 2-year OS was 84% in patients without tsAML. Nineteen patients (32%) transitioned to stem cell transplant, and 51% remain on study. CONCLUSION: Given the excellent outcomes of IDH-triplet therapy for newly diagnosed, IC-ineligible IDH -mutant AML, further prospective studies comparing IDH-triplet versus IDH-doublet regimens are warranted.

19 June 2025 in Blood
Verified
Journal Article
Open access
PRPatrick K. Reville
Patrick K. Reville
BWBofei Wang
Bofei Wang
JMJennifer Marvin-Peek
Jennifer Marvin-Peek
BYBin Yuan
Bin Yuan
YKYu-An Kuo
Yu-An Kuo
HAHussein A. Abbas
Hussein A. Abbas
Inflammation is increasingly recognized as a critical factor in acute myeloid leukemia (AML) pathogenesis. We performed blood-based proteomic profiling of 251 inflammatory proteins in 543 patients with newly diagnosed AML. Using a machine learning model, we derived an 8-protein prognostic score termed the leukemia inflammatory risk score (LIRS). Individual proteins were evaluated in multivariable Cox models, and model performance was assessed by cumulative concordance index. Findings were validated in internal and external cohorts across 2 institutions. Blood-based LIRS significantly outperformed the European LeukemiaNet 2022 risk model and was independently prognostic of overall survival after accounting for known clinical and molecular prognostic factors. Oncostatin M receptor was uniquely identified as the strongest independent predictor of survival, early mortality, and induction chemotherapy response, and further validated in an independent assay. These blood-based biomarkers could have significant clinical implications for risk stratification and prognostication in patients with newly diagnosed AML.

25 November 2024 in Cancer
Verified
Journal Article
Closed access
WJWei Ying Jen
Wei Ying Jen
JMJennifer Marvin‐Peek
Jennifer Marvin‐Peek
HKHagop M. Kantarjian
Hagop M. Kantarjian
YAYesid Alvarado
Yesid Alvarado
GBGautam Borthakur
Gautam Borthakur
Farhad RavandiFarhad Ravandi
Farhad Ravandi

8 February 2025 in American Journal of Hematology
Verified
Journal Article
Closed access
JSJayastu Senapati
Jayastu Senapati
SLSanam Loghavi
Sanam Loghavi
JMJennifer Marvin‐Peek
Jennifer Marvin‐Peek
GGGuillermo Garcia‐Manero
Guillermo Garcia‐Manero
TKTapan M. Kadia
Tapan M. Kadia
CDCourtney Dinardo
Courtney Dinardo

9 March 2023 in Transplantation and Cellular Therapy
Verified
Journal Article
Open access
JMJennifer Marvin-Peek
Jennifer Marvin-Peek
EMEmily F. Mason
Emily F. Mason
AKAshwin Kishtagari
Ashwin Kishtagari
RJReena V. Jayani
Reena V. Jayani
BDBhagirathbhai Dholaria
Bhagirathbhai Dholaria
MBMichael Byrne
Michael Byrne
Although allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for patients with poor-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), only a minority of these patients undergo HCT. Patients with TP53-mutated (TP53MUT) MDS/AML are at particularly high risk, yet fewer TP53MUT patients undergo HCT compared with poor-risk TP53-wild type (TP53WT) patients. We hypothesized that TP53MUT MDS/AML patients have unique risk factors affecting the rate of HCT and thus investigated phenotypic changes that may prevent patients with TP53MUT MDS/AML from receiving HCT. In this single-center retrospective analysis of outcomes for adults with newly diagnosed MDS or AML (n = 352), HLA typing was used as a surrogate for physician "intent to transplant." Multivariable logistic regression models were used to estimate odds ratios (ORs) for factors associated with HLA typing, HCT, and pretransplantation infections. Multivariable Cox proportional hazards models were used to create predicted survival curves for patients with and those without TP53 mutations. Overall, significantly fewer TP53MUT patients underwent HCT compared to TP53WT patients (19% versus 31%; P = .028). Development of infection was significantly associated with decreased odds of HCT (OR, .42; 95% CI, .19 to .90) and worse overall survival (hazard ratio, 1.46; 95% CI, 1.09 to 1.96) in multivariable analyses. TP53MUT disease was independently associated with increased odds of developing an infection (OR, 2.18; 95% CI, 1.21 to 3.93), bacterial pneumonia (OR, 1.83; 95% CI, 1.00 to 3.33), and invasive fungal infection (OR, 2.64; 95% CI, 1.34 to 5.22) prior to HCT. Infections were the cause of death in significantly more patients with TP53MUT disease (38% versus 19%; P = .005). With substantially more infections and decreased HCT rates in patients with TP53 mutations, this raises the possibility that phenotypic changes occurring in TP53MUT disease may affect infection susceptibility in this population and drastically impact clinical outcomes.

15 May 2024 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
JMJennifer Marvin-Peek
Jennifer Marvin-Peek
WJWei Ying Jen
Wei Ying Jen
HKHagop M. Kantarjian
Hagop M. Kantarjian
DMDavid McCue
David McCue
FHFadi G. Haddad
Fadi G. Haddad
Farhad RavandiFarhad Ravandi
Farhad Ravandi
We report on the long-term efficacy and safety of a phase 2 trial of sequential cladribine and rituximab in hairy cell leukemia (HCL). One-hundred and thirty-nine patients were enrolled: 111 in the frontline setting, 18 in first relapse, and 10 with variant HCL (HCLv). A complete response (CR) was achieved in 133 of 137 evaluable participants (97%) with measurable residual disease (MRD) negativity in 102 (77%). MRD status was not associated with significant differences in event-free survival (EFS) or overall survival (OS). With a median follow-up of 7.8 years (range: 0.40-18.8), eight patients have experienced disease relapse (5.8%), 4/111 with newly diagnosed HCL (3·6%) and 4/10 with HCLv (40%) (p = 0.002). The 10-year EFS and OS rates were 86.7% and 91.1%, respectively. Grade 3 adverse events were observed in 28 participants (20·1%), mostly due to infections. Treatment of HCL with sequential cladribine followed by rituximab is associated with excellent efficacy and safety results both in the frontline and relapsed settings.